Impact of benralizumab on airway structure/function in severe eosinophilic asthma.

Donna D Carstens¹, Wilfried De Backer^2,3, Kirsty Rhodes⁴, Patrick Muchmore², Benjamin R Lavon², Sze Yan Ernestine Chung², Robert Fogel⁵, Frank Trudo⁶, Reynold Panettieri⁷

¹BioPharmaceuticals Medical - US, AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19803, USA. donna.carstens@astrazeneca.com.

²FLUIDDA, New York, NY, USA.

³Faculty of Medicine, University of Antwerp, Antwerp, Belgium.

⁴BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.

⁵BioPharmaceuticals Medical - US, AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19803, USA.

⁶BioPharmaceuticals, Global Patient Safety, AstraZeneca, Wilmington, DE, USA.

⁷Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.

PubMed DOI

Abstract

BACKGROUND: The BURAN study (ClinicalTrials.gov: NCT05552508) was a multicenter open-label study evaluating airway structure/function changes in adults with severe eosinophilic asthma (SEA) following eosinophil depletion by benralizumab. We assessed the changes in airway structure/function following treatment with benralizumab in adults with SEA. METHODS: We recruited adults (18-70 years) with SE…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.